Swiss National Bank Has $2.15 Million Stock Holdings in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH)

Swiss National Bank decreased its position in shares of Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) by 9.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 239,000 shares of the biotechnology company’s stock after selling 26,200 shares during the quarter. Swiss National Bank owned about 0.17% of Aurinia Pharmaceuticals worth $2,146,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of AUPH. Intech Investment Management LLC bought a new position in shares of Aurinia Pharmaceuticals during the third quarter worth $262,000. Charles Schwab Investment Management Inc. grew its stake in Aurinia Pharmaceuticals by 13.7% in the third quarter. Charles Schwab Investment Management Inc. now owns 744,050 shares of the biotechnology company’s stock valued at $5,454,000 after acquiring an additional 89,940 shares during the period. FMR LLC increased its holdings in shares of Aurinia Pharmaceuticals by 44.8% in the third quarter. FMR LLC now owns 12,673 shares of the biotechnology company’s stock worth $93,000 after acquiring an additional 3,919 shares in the last quarter. BNP Paribas Financial Markets increased its holdings in shares of Aurinia Pharmaceuticals by 172.9% in the third quarter. BNP Paribas Financial Markets now owns 32,078 shares of the biotechnology company’s stock worth $235,000 after acquiring an additional 20,324 shares in the last quarter. Finally, Verition Fund Management LLC raised its position in shares of Aurinia Pharmaceuticals by 209.0% during the third quarter. Verition Fund Management LLC now owns 58,518 shares of the biotechnology company’s stock worth $429,000 after purchasing an additional 39,583 shares during the period. Institutional investors and hedge funds own 36.83% of the company’s stock.

Wall Street Analyst Weigh In

Separately, StockNews.com raised Aurinia Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday.

Aurinia Pharmaceuticals Stock Performance

AUPH opened at $8.46 on Friday. The company has a market capitalization of $1.16 billion, a price-to-earnings ratio of -56.40 and a beta of 1.26. The business’s 50-day moving average price is $8.09 and its two-hundred day moving average price is $8.02. Aurinia Pharmaceuticals Inc. has a 1 year low of $4.71 and a 1 year high of $10.67. The company has a debt-to-equity ratio of 0.17, a current ratio of 5.60 and a quick ratio of 5.11.

Insider Buying and Selling

In other news, CEO Peter Greenleaf sold 195,593 shares of the firm’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $8.00, for a total value of $1,564,744.00. Following the completion of the transaction, the chief executive officer now owns 1,953,892 shares in the company, valued at $15,631,136. This trade represents a 9.10 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Greg Keenan sold 12,239 shares of the company’s stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $8.00, for a total value of $97,912.00. Following the sale, the insider now owns 161,789 shares in the company, valued at $1,294,312. The trade was a 7.03 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 343,898 shares of company stock worth $2,753,094. 4.30% of the stock is owned by corporate insiders.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.